Collectively, these data suggest that XPO1 worsens the survival of DLBCL patients with unfavorable prognostic factors such as BCL2 overexpression and double-hit, in line with the higher efficacy of selinexor demonstrated in BCL2-R<sup>+</sup> DLBCL and HGBCL-DH cell lines. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.